ARTICLE | Distillery Therapeutics
Neurology
November 26, 2018 8:11 PM UTC
Rat studies suggest glycyrrhizin could help treat status epilepticus. In a rat model of lithium-pilocarpine-induced status epilepticus, glycyrrhizin -- which inhibits HMGB1 -- decreased blood-brain barrier (BBB) disruption and hippocampal neuronal damage and increased survival compared with vehicle. Next steps could include testing the compound in other models of status epilepticus.
Applied Immunotherapeutics Inc. has the small molecule HMGB1 inhibitors K557 and K883 in preclinical testing for autoimmune diseases...
BCIQ Company Profiles
BCIQ Target Profiles